Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,otherCurrentAssets,otherCurrentLiab,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,investments,totalCashflowsFromInvestingActivities,issuanceOfStock,repurchaseOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,HBPCF,1310000.0,102810000,1933000,,-2554000,,-2554000,651000,0,-2584000,-2584000,,-3000,,,,0,0,2584000,0,30000,,-2554000,-2554000,27331000.0,1713000.0,1310000.0,3023000.0,139660000.0,-185784000.0,20103000.0,2266000.0,1713000.0,20103000.0,87000.0,2936000.0,392000.0,1265000.0,,,424000.0,-33000.0,-33000.0,195000.0,-1832000.0,33000.0,-1832000.0,40000.0,-2000.0,65000.0,,,,,,1223000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.04453859,0,PRE,PNK,False,False,0.67,1630521420,-0.0079,0.67,0.67,0.67,1000,74.44445,15,America/New_York,EDT,4,-1.1653636,0.67 - 0.67,0.6779,0.0,0.0,0,0,finmb_876399,Other OTC,Helix BioPharma Corp.,CAD,139,0,0.45000002,2.0454547,0.22 - 0.88,-0.20999998,-0.23863634,0.22,0.88,-0.044,-14400000,0.009,0.6942857,-0.024285674,-0.034979366,0.7012319,-0.03123188,63302468,HELIX BIOPHARMA CORP,-0.16,,,0.88,0.22,0.6943,0.7012,139,,102.81M,,119.81M,15.11%,18.68%,,,,,,,,,,,,,,,,"Jul 30, 2020","Apr 29, 2021",0.00%,0.00%,-129.66%,-334.48%,,,,,-8.86M,-8.74M,-0.0440,,2.27M,0.02,34k,2.60,1.71,0.01,-9.39M,-4.7M,Value,L4B 3J9,,10,"Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.",Richmond Hill,905 841 2300,ON,1609372800,Canada,http://www.helixbiopharma.com,86400,9120 Leslie Street,905 841 2244,,Suite 205
t-1,HBPCF,3766000.0,102810000,1086000,,-1866000,,-2492000,818000,0,-1904000,-1904000,,-4000,,,,0,0,1904000,0,38000,-626000.0,-1866000,-2492000,27201000.0,1235000.0,3766000.0,5001000.0,139660000.0,-183230000.0,20135000.0,4098000.0,1235000.0,20135000.0,127000.0,4874000.0,390000.0,841000.0,,,-846000.0,-9000.0,3552000.0,-88000.0,2670000.0,43000.0,-2945000.0,21000.0,-224000.0,684000.0,2020000.0,2020000.0,3561000.0,,,3639000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.04453859,0,PRE,PNK,False,False,0.67,1630521420,-0.0079,0.67,0.67,0.67,1000,74.44445,15,America/New_York,EDT,4,-1.1653636,0.67 - 0.67,0.6779,0.0,0.0,0,0,finmb_876399,Other OTC,Helix BioPharma Corp.,CAD,139,0,0.45000002,2.0454547,0.22 - 0.88,-0.20999998,-0.23863634,0.22,0.88,-0.044,-14400000,0.009,0.6942857,-0.024285674,-0.034979366,0.7012319,-0.03123188,63302468,HELIX BIOPHARMA CORP,-0.16,,,0.88,0.22,0.6943,0.7012,139,,102.81M,,119.81M,15.11%,18.68%,,,,,,,,,,,,,,,,"Jul 30, 2020","Apr 29, 2021",0.00%,0.00%,-129.66%,-334.48%,,,,,-8.86M,-8.74M,-0.0440,,2.27M,0.02,34k,2.60,1.71,0.01,-9.39M,-4.7M,Value,L4B 3J9,,10,"Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.",Richmond Hill,905 841 2300,ON,1609372800,Canada,http://www.helixbiopharma.com,86400,9120 Leslie Street,905 841 2244,,Suite 205
t-2,HBPCF,2596000.0,102810000,1084000,,-2384000,,-222000,1303000,0,-2387000,-2387000,,-4000,,,,0,0,2387000,0,3000,2162000.0,-2384000,-222000,27141000.0,1982000.0,2596000.0,4578000.0,137257000.0,-180738000.0,18936000.0,1428000.0,1982000.0,18936000.0,170000.0,4408000.0,166000.0,1685000.0,2646000.0,,271000.0,-60000.0,-60000.0,-182000.0,-2807000.0,5000.0,-2752000.0,76000.0,14000.0,-2709000.0,2020000.0,2020000.0,3561000.0,,,2426000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.04453859,0,PRE,PNK,False,False,0.67,1630521420,-0.0079,0.67,0.67,0.67,1000,74.44445,15,America/New_York,EDT,4,-1.1653636,0.67 - 0.67,0.6779,0.0,0.0,0,0,finmb_876399,Other OTC,Helix BioPharma Corp.,CAD,139,0,0.45000002,2.0454547,0.22 - 0.88,-0.20999998,-0.23863634,0.22,0.88,-0.044,-14400000,0.009,0.6942857,-0.024285674,-0.034979366,0.7012319,-0.03123188,63302468,HELIX BIOPHARMA CORP,-0.16,,,0.88,0.22,0.6943,0.7012,139,,102.81M,,119.81M,15.11%,18.68%,,,,,,,,,,,,,,,,"Jul 30, 2020","Apr 29, 2021",0.00%,0.00%,-129.66%,-334.48%,,,,,-8.86M,-8.74M,-0.0440,,2.27M,0.02,34k,2.60,1.71,0.01,-9.39M,-4.7M,Value,L4B 3J9,,10,"Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.",Richmond Hill,905 841 2300,ON,1609372800,Canada,http://www.helixbiopharma.com,86400,9120 Leslie Street,905 841 2244,,Suite 205
t-3,HBPCF,2394000.0,102810000,1267000,,-1966000,587000.0,-2089000,762000,0,-2029000,-2029000,,-13000,,,,0,0,2029000,0,63000,-148000.0,-1966000,-2089000,25540000.0,1925000.0,2394000.0,4906000.0,137257000.0,-180516000.0,20113000.0,4235000.0,1925000.0,20113000.0,246000.0,4660000.0,180000.0,1416000.0,155000.0,49000.0,325000.0,-151000.0,912000.0,-118000.0,-866000.0,82000.0,-1860000.0,172000.0,16000.0,-166000.0,2020000.0,2020000.0,3561000.0,-4458000.0,5521000.0,2735000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.04453859,0,PRE,PNK,False,False,0.67,1630521420,-0.0079,0.67,0.67,0.67,1000,74.44445,15,America/New_York,EDT,4,-1.1653636,0.67 - 0.67,0.6779,0.0,0.0,0,0,finmb_876399,Other OTC,Helix BioPharma Corp.,CAD,139,0,0.45000002,2.0454547,0.22 - 0.88,-0.20999998,-0.23863634,0.22,0.88,-0.044,-14400000,0.009,0.6942857,-0.024285674,-0.034979366,0.7012319,-0.03123188,63302468,HELIX BIOPHARMA CORP,-0.16,,,0.88,0.22,0.6943,0.7012,139,,102.81M,,119.81M,15.11%,18.68%,,,,,,,,,,,,,,,,"Jul 30, 2020","Apr 29, 2021",0.00%,0.00%,-129.66%,-334.48%,,,,,-8.86M,-8.74M,-0.0440,,2.27M,0.02,34k,2.60,1.71,0.01,-9.39M,-4.7M,Value,L4B 3J9,,10,"Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.",Richmond Hill,905 841 2300,ON,1609372800,Canada,http://www.helixbiopharma.com,86400,9120 Leslie Street,905 841 2244,,Suite 205
